Keyword: X4 Pharmaceuticals
Setting the dose of the CXCR4 inhibitor tees X4 up to start the phase 3 portion of the rare immunodeficiency disease trial before the end of the year.
X4 Pharma said the 23% objective response rate was "encouraging" as it was observed in third-line patients, a group whose response rate hovers around 10%.
A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.
The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.
Yale University has teamed up with cancer biotech X4 Pharma to work on its therapy for WHIM syndrome, a rare genetic disorder.